Skip to content
Markets News
Earnings1 min read

Novo Lifts 2026 Outlook After Wegovy Pill Beats Estimates

Makkler Newsroom
November 4, 2026 · Based on reporting by GlobeNewswire, CNBC, finanzen.net

Novo Nordisk raised its adjusted growth outlook after third-quarter sales and operating profit exceeded estimates, led by continued demand for its obesity treatments.

Key takeaways

  • Novo raised its 2026 adjusted sales and operating profit growth outlook to -2% to +2% at constant exchange rates.
  • Third-quarter sales were DKK 79.2 billion, up 4% at constant exchange rates.
  • Wegovy pill sales reached DKK 5,394 million in the quarter.

Novo Nordisk raised its 2026 outlook after third-quarter sales and adjusted operating profit beat expectations, with Wegovy pill sales reaching DKK 5,394 million. The company now expects adjusted sales and operating profit growth of -2% to +2% at constant exchange rates.

The new range compares with its previous forecast of -6% to flat growth for both measures. Novo said the improved outlook reflects higher expectations for GLP-1 product sales.

Third-quarter sales rose 4% at constant exchange rates to DKK 79.2 billion, above FactSet’s DKK 73.6 billion estimate. Adjusted operating profit increased 27% at constant exchange rates to DKK 31,720 million, compared with an analyst estimate of DKK 28.6 billion, according to CNBC.

Reported operating profit moved in the opposite direction, falling 9% at constant exchange rates. Novo attributed the decline to DKK 8.7 billion in non-cash impairment charges related to ziltivekimab and changes to its manufacturing network.

The Wegovy pill had launched in the US, UAE, UK and Germany by quarter-end. Novo said subsequent launches in four more countries brought the total number of markets to eight.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.